RTAC: FES/Cerianna Screening for Estrogen Positive MBC
There’s a FDA- approved diagnostic imaging agent developed to comprehensively evaluate estrogen receptor-positive (ER+) lesions in recurrent or metastatic breast cancer as an adjunct to biopsy. By creating a “whole-body” picture of ER+ lesions, Cerianna may be a helpful diagnostic tool in helping oncologists better determine the most appropriate course of treatment. Learn more in this episode.
Psilocybin-assisted Therapy: One Patient vs. the DEA
Welcome to the third and final episode in our series on the potential of psilocybin-assisted therapy to relieve the existential distress of, and help us live as well as possible with, metastatic breast cancer.
In this episode, we speak with two women taking action to increase legal access to psilocybin-assisted therapy in the United States. The first is a patient living with MBC who, along with her doctor, have brought a lawsuit against the Drug Enforcement Agency which is denying her access to psilocybin in the palliative care setting and under existing Right to Try laws for promising investigational medications for the terminally ill. The patient petitioner, Erinn Baldeschwiler, tells us why she joined the lawsuit, what she hopes to gain from psilocybin-assisted therapy, and what it’s been like to deal with all the legal proceedings on top of a progressing MBC diagnosis.
Our second interview in this episode is with the attorney who is leading the legal case to open access to psilocybin under Right to Try legislation, Kathryn Tucker of the Emerge Law Group. Kathryn explains why psilocybin should be immediately available to patients suffering from distress, anxiety, depression under FDA rules and state and federal Right to Try laws. But the DEA is continuing to block access and hold psilocybin on Schedule 1 of the Controlled Substance Act.
It’s confusing, but we explain it all here. Lastly, see the Episode Notes for a current petition to the DEA to step out of the way and grant access to psilocybin for anyone with a terminal illness.
This series has been led by series producer, Dr. Paula Jayne with assistance from co-host Lynda Weatherby, and senior producer and host Lisa Laudico.
Thanks for listening!
Psilocybin-assisted Therapy: Patient Experiences
Welcome to the second episode in our series on the potential of psilocybin-assisted therapy to help us live as well as possible with metastatic breast cancer.
In this episode, we talk to two women with breast cancer who had legal access to psilocybin-assisted therapy. Journalist and writer Erica Rex participated in a clinical trial at Johns Hopkins after being diagnosed with early-stage breast cancer. Mari Singfield, a young Canadian woman living with MBC, gained access through an exemption to Section 56(1) of the Canadian Controlled Drugs and Substances Act, a process facilitated by the organization, TheraPsil.
Both women shared with us the process that they went through to gain legal access to psilocybin-assisted therapy, what the treatment was actually like for them, and what, if anything, changed in their lives afterward.
Healing our Distress: The Potential of Psilocybin-assisted Therapy
Welcome to our series on the potential of psilocybin-assisted therapy to help us live as well as possible with metastatic breast cancer.
In this first episode, co-host and producer of this series, Dr. Paula Jayne and co-host Lynda Weatherby interview Dr. Boadie Dunlop, Director of the Mood and Anxiety Disorders Program at Emory University. Dr Dunlop shares existing and emerging data on how psilocybin may help those of us living with MBC and discusses an upcoming pilot trial of psilocybin-assisted therapy at Emory University’s Palliative and Supportive Care Clinic.
Grief, Loss, & Faith
All of us approach life and death in general from the perspective of our faith traditions, our family cultures, and the traditions and culture we choose as adults.